Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
ROCKVILLE, Md., Feb. 18, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the fourth quarter and full year of 2015 after 5:00 PM ET on Wednesday, March 2, 2016.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the fourth quarter and full year 2015 results on Thursday, March 3, 2016 at 9:00 AM ET. Following the presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | ||
| International dial-in: | (970) 315-0267 | ||
| Conference ID: | 47017444 | ||
| Conference Call Name: | Supernus Pharmaceuticals 4Q 2015 Earnings Conference Call | ||
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in patients who are already being treated with standard ADHD medication. SPN-812 is being developed for treatment of ADHD.
CONTACTS: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
